Hong Youngki, Kim Jaelim, Choi Yoon Jung, Kang Jung Gu
Department of Surgery, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
Department of Pathology, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
Korean J Clin Oncol. 2020 Jun;16(1):3-8. doi: 10.14216/kjco.20002. Epub 2020 Jun 30.
Overall 5-year survival rates for colon and rectal cancer reported recently by the American Cancer Society were 89%, 90% for localized disease, 71%, 71% for regional disease, and 14%, 15% for distant disease. But the results of survival rate of colorectal cancer in a single institution were very rare. The aim of this study is to evaluate surgical results and survival rates of colorectal cancer.
We conducted a retrospective study with patients who underwent curative resection for a primary colorectal adenocarcinoma between 2009 and 2018.
Five-year overall and disease-free survival were 79.5% and 69.9%, respectively. The overall 5-year survival by stages was 94.7% in stage I, 88.4% in stage II, 74.3% in stage III and 31.5% in stage IV. Five-year disease-free survival was 91% in stage I, 79.8% in stage II, 63.3% in stage III, and 18.9% in stage IV. The overall 5-year survival in rectal cancer was superior to colon cancer (P=0.014) while there was no difference in 5-year disease-free survival (P=0.338). Overall survival in female patients was better than male patient (P=0.029). Overall survival by age was worst in group of less than 40 years old (62.5%), and best in group between 41 and 65 years old (86.5%). Postoperative mortality within 30 days was 0.4%, and the recurrence rate was 19.2%.
With the development of surgical skills and various treatments, postoperative outcome of colorectal cancer is expected to improve. It may be helpful for surgeons to improve their surgical outcomes when they review their data and conduct active researches.
美国癌症协会最近报告的结肠癌和直肠癌总体5年生存率分别为89%、90%(局限性疾病)、71%、71%(区域性疾病)以及14%、15%(远处疾病)。但单机构结直肠癌生存率的结果非常少见。本研究的目的是评估结直肠癌的手术结果和生存率。
我们对2009年至2018年间接受原发性结直肠腺癌根治性切除术的患者进行了一项回顾性研究。
5年总生存率和无病生存率分别为79.5%和69.9%。各分期的5年总生存率分别为:I期94.7%,II期88.4%,III期74.3%,IV期31.5%。5年无病生存率分别为:I期91%,II期79.8%,III期63.3%,IV期18.9%。直肠癌的5年总生存率优于结肠癌(P = 0.014),而5年无病生存率无差异(P = 0.338)。女性患者的总生存率优于男性患者(P = 0.029)。按年龄划分的总生存率在40岁以下组最差(62.5%),在41至65岁组最佳(86.5%)。30天内术后死亡率为0.4%,复发率为19.2%。
随着手术技术和各种治疗方法的发展,结直肠癌的术后结局有望改善。外科医生回顾其数据并开展积极研究可能有助于改善他们的手术结果。